Dr. Tamar Grossman, a seasoned industry leader, to play a key role in strengthening AGS Therapeutics’ leadership, strategic direction, and the internationalization of its Board of Directors.

‍

EVRY, FRANCE, February 13th, 2025 – AGS Therapeutics, a preclinical-stage biotech company pioneering Microalgae Extracellular Vesicles (MEVs) as a novel, universal delivery system, today announced the appointment of Dr. Tamar Grossman as an Independent Director to its Board. 

‍

‍

Dr. Grossman brings extensive experience and a distinguished track record in strategic development within the pharmaceutical and biotech sectors. With over 15 years of experience in leadership roles at Ionis Pharmaceuticals, Arcturus Therapeutics, Johnson & Johnson, and currently as CEO of La Jolla Labs, she has demonstrated her ability to drive innovation, develop strategies, and deliver transformative medicines to patients with unmet medical needs using a broad range of genomic medicine modalities.

‍

As an Independent Director, Dr. Grossman will provide invaluable insights into AGS Therapeutics’ strategic initiatives, leveraging her expertise in drug discovery and pharmaceutical strategy. Previously, as Vice President and Global Head of RNA, Gene Therapy, and Delivery at Johnson & Johnson Innovative Medicine, she built a successful strategy for genetic medicine drug modalities and delivered multiple drug candidates and vaccines across a broad range of therapeutic areas.

‍

“We are delighted to welcome Tamar to our Board of Directors,” said Manuel Vega, CEO of AGS Therapeutics. “She is a widely respected leader in the biotech-pharma community, known for her strategic acumen, deep industry expertise, and ability to navigate complexity while uniting diverse stakeholders. Her distinguished career includes executive roles at leading pharmaceutical companies, where she has driven innovation and transformative initiatives. Tamar’s natural authority, composed leadership style, and exceptional emotional intelligence make her an invaluable addition to AGS. As we continue advancing our pioneering MEV technology, her insight, experience, and steady guidance will play a crucial role in shaping our future.”

‍

Dr. Grossman expressed her enthusiasm about joining AGS Therapeutics: "I am thrilled to join the AGS Therapeutics Board of Directors at such a pivotal time for the company. I am particularly excited by the potential of Microalgae Extracellular Vesicles (MEVs) as a truly innovative delivery platform for therapeutics. I believe AGS's pioneering work in this area has the potential to revolutionize how we treat a wide range of diseases, and I look forward to contributing my expertise to help the company realize its ambitious goals." 

‍

Dr. Grossman holds a PhD in Biochemistry from Tel Aviv University and completed her postdoctoral research training at UC San Diego, where she focused on deciphering disease mechanisms for rare and complex genetic disorders. Throughout her career, she has gained broad expertise in the research and development of RNA therapeutics modalities, including siRNA, ASO, mRNA, and replicon/saRNA. At Johnson & Johnson, as VP and Global Head of RNA, Gene Therapy, and Delivery, she led teams responsible for developing RNA-based therapies, gene therapies, and ADCs across multiple therapeutic areas. Prior to J&J, she was Head of Rare Diseases at Arcturus Therapeutics, where she developed RNA-based therapeutics for both rare and common diseases. Before that, she served as Director of Translational Medicine at Ionis Pharmaceuticals, leading antisense oligonucleotide therapeutic programs from concept through successful clinical development.

‍

‍

About AGS

‍

AGS Therapeutics, based in Paris and at Genopole (www.genopole.fr), Evry, France, is a biotech company pioneering the use of microalgae extracellular vesicles (MEVs) as a universal delivery system for innovative therapeutics, vaccines and gene therapies. AGS has shown MEVs to be a safe, targeted and highly versatile delivery system for mRNA, siRNA, DNA oligos, plasmids, proteins, and peptides relevant to a broad range of human diseases. AGS's programs include AGS-1010 and AGS-2010. AGS-1010 carries an anti-angiogenesis agent loaded into MEVs and is intended for the treatment of wAMD. AGS-1010 can be delivered to the back of the eye-by-eye drops (drop instillation), which differentiates it from all products (in the market or in development, for the treatment of wAMD). AGS-2010 carries a modulator of TLR-9 activity, loaded into MEVs, and is intended for the treatment of IBD. AGS-2010 is delivered directly to the intestinal epithelila cells followiong the oral administration of the loaded MEVs. AGS-2010 differentiates from current treatments of IBD by the highly targeted delivery to the site of action (the intestine) through the intestinal lumen, thus avoiding the systemic route. AGS-M, the company’s CDMO subsidiary, produces the MEVs needed to support R&D at AGS and for companies partnering with AGS. AGS’s MEVs are derived from Chlorella, a two-billion-year-old single-cell algae, labelled by the FDA as GRAS for consumption as a food supplement. AGS’s MEVs are easy to manufacture in large quantities with processes that are sustainable, straightforward (simple), scalable, resource-effective, and cost-effective. Through strategic partnerships and a commitment to scientific excellence, the company aims to challenge the delivery landscape and improve the lives of patients across the globe. For more information, visit www.ags-tx.com and www.ags-m.com.

‍

‍

Forward-looking statement

‍

This announcement may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on the future, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this communication.

‍

‍

Contacts

‍

Marie-Hélène Leopold

AGS Therapeutics

+33 (0)6 07 16 55 01

mhl@ags-tx.com

‍

Ana Vega

Markets & Listing

+33 (0)6 88 57 05 77

av@markets-listing.com